# Pioglitazone for Oral Premalignant Lesions

> **NCT00951379** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 52 (actual)

## Conditions studied

- Oral Leukoplakia

## Interventions

- **DRUG:** Pioglitazone hydrochloride
- **OTHER:** placebo
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00951379
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Due to slow accrual.
- **Last updated:** 2016-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00951379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00951379, "Pioglitazone for Oral Premalignant Lesions". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00951379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*